Positive Results For ReoPro In CAPTURE Trial
Centocor has halted the 1,400-patient CAPTURE trial of its glycoprotein IIb/IIIa antibody, ReoPro (abciximab; 7E3), in refractory unstable angina patients scheduled for coronary angioplasty due to positive findings at an interim analysis of 1,050 patients. The results of the interim analysis were reviewed by an independent monitoring committee, which concluded that the trial should be stopped early because efficacy in the primary endpoint (death, myocardial infarction or the need for urgent intervention within 30 days of treatment) exceeded the predetermined stopping rule.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze